东诚药业：拟3600万元收购控股子公司蓝纳成少数股东股权

Group 1 - The company Dongcheng Pharmaceutical plans to acquire 1.65% equity stake from a minority shareholder of its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. for approximately 36 million RMB [1] - The acquisition is aimed at consolidating control over the subsidiary, which may enhance operational efficiency and strategic alignment [1] - This move reflects the company's ongoing strategy to strengthen its position in the biotechnology sector [1]